Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition

Regulus Therapeutics drug farabursen is a potential first-in-class treatment for a rare kidney disease whose only FDA-approved therapy introduces severe toxicity risks. Farabursen is joining a Novartis drug lineup spanning several therapies for rare renal disorders. The post Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition appeared first on MedCity News.

Read More

Do Gun-Purchase Waiting Periods Save Lives?

That is the title of a paper by Arnold and Priestley (2025). They examine whether gun purchase wait periods impact suicide rates using both variation in gun laws by state over time as well as variation in a county’s distance to the nearest state without a waiting period. First, some background on US gun purchase…

Read More